title: Antibody therapeutics for Ebola virus disease.
abstract: With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.
authors.affiliation: Mapp Biopharmaceutical, Inc., 6160 Lusk Blvd #C105, San Diego, CA 92121, USA. Electronic address: larry.zeitlin@mappbio.com.
authors.forename: Larry
authors.initials: L
authors.lastname: Zeitlin
authors.affiliation: Mapp Biopharmaceutical, Inc., 6160 Lusk Blvd #C105, San Diego, CA 92121, USA.
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Whaley
authors.affiliation: Integrated Research Facility, 8200 Research Plaza Frederick, MD 21702, USA.
authors.forename: Gene G
authors.initials: GG
authors.lastname: Olinger
authors.affiliation: Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, United Kingdom.
authors.forename: Michael
authors.initials: M
authors.lastname: Jacobs
authors.affiliation: High Containment Microbiology Department, National Infections Service, Public Health England, 61 Colindale Avenue, London NW9 5HT, United Kingdom.
authors.forename: Robin
authors.initials: R
authors.lastname: Gopal
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada; Department of Medical Microbiology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada.
authors.forename: Xiangguo
authors.initials: X
authors.lastname: Qiu
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada; Department of Medical Microbiology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada; Department of Immunology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada.
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004196:Disease Outbreaks; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D008251:Macaca / Q000276:immunology / Q000821:virology; D011323:Primates / Q000276:immunology / Q000821:virology; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal
references.citation: Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20690-4
references.pmid: 22143789
references.citation: Sci Transl Med. 2013 Aug 21;5(199):199ra113
references.pmid: 23966302
references.citation: J Infect Dis. 2007 Nov 15;196 Suppl 2:S400-3
references.pmid: 17940976
references.citation: Nature. 2014 Oct 2;514(7520):47-53
references.pmid: 25171469
references.citation: Emerg Infect Dis. 1999 Jan-Feb;5(1):54-64
references.pmid: 10081672
references.citation: J Virol. 2002 Jun;76(12):6408-12
references.pmid: 12021376
references.citation: Nat Rev Microbiol. 2009 May;7(5):393-400
references.pmid: 19369954
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5
references.pmid: 23071322
references.citation: N Engl J Med. 2014 Dec 18;371(25):2350-1
references.pmid: 25470568
references.citation: PLoS Pathog. 2007 Jan;3(1):e9
references.pmid: 17238286
references.citation: Microbes Infect. 2000 May;2(6):701-8
references.pmid: 10884621
references.citation: PLoS One. 2012;7(4):e36192
references.pmid: 22558378
references.citation: Sci Transl Med. 2012 Jun 13;4(138):138ra81
references.pmid: 22700957
references.citation: Pediatrics. 2006 Jan;117(1):e76-83
references.pmid: 16326692
references.citation: Sci Transl Med. 2012 Oct 31;4(158):158ra146
references.pmid: 23115355
references.citation: J Virol. 1999 Jul;73(7):6024-30
references.pmid: 10364354
references.citation: Bull World Health Organ. 1973 May;48(5):517-22
references.pmid: 4359678
references.citation: Nat Biotechnol. 2005 Sep;23(9):1073-8
references.pmid: 16151394
references.citation: Vaccine. 2007 Jan 22;25(6):993-9
references.pmid: 17055127
references.citation: Lab Anim Sci. 1988 Apr;38(2):194-6
references.pmid: 3374098
references.citation: J Infect Dis. 2015 Dec 1;212(11):1752-8
references.pmid: 26002981
references.citation: Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9
references.pmid: 22411795
references.citation: Arch Virol Suppl. 1996;11:135-40
references.pmid: 8800795
references.citation: BioDrugs. 2007;21(1):1-7
references.pmid: 17263584
references.citation: Clin Infect Dis. 1995 Jul;21(1):150-61
references.pmid: 7578724
references.citation: Pediatr Infect Dis J. 2014 Jul;33(7):703-9
references.pmid: 24356256
references.citation: J Infect Dis. 1999 Feb;179 Suppl 1:S218-23
references.pmid: 9988187
references.citation: J Infect Dis. 1999 Feb;179 Suppl 1:S18-23
references.pmid: 9988160
references.citation: J Infect Dis. 1999 Feb;179 Suppl 1:S224-34
references.pmid: 9988188